13.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.51
Aprire:
$13.45
Volume 24 ore:
728.41K
Relative Volume:
1.08
Capitalizzazione di mercato:
$715.22M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-5.5274
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
-0.91%
1M Prestazione:
+10.92%
6M Prestazione:
+23.35%
1 anno Prestazione:
-10.03%
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
STOK
Stoke Therapeutics Inc
|
13.10 | 737.60M | 8.78M | -104.70M | -82.68M | -2.37 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-18 | Iniziato | Jefferies | Buy |
2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
2024-10-14 | Ripresa | Leerink Partners | Outperform |
2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
2023-11-20 | Ripresa | JP Morgan | Neutral |
2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
2023-04-26 | Ripresa | Canaccord Genuity | Buy |
2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-01-31 | Iniziato | Jefferies | Buy |
2021-12-03 | Iniziato | BofA Securities | Buy |
2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-05-18 | Iniziato | UBS | Neutral |
2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
2020-12-15 | Ripresa | H.C. Wainwright | Buy |
2020-12-11 | Reiterato | Needham | Buy |
2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
2020-09-29 | Ripresa | JP Morgan | Neutral |
2020-09-29 | Iniziato | Needham | Buy |
2019-12-18 | Iniziato | Wedbush | Outperform |
2019-11-12 | Iniziato | BTIG Research | Buy |
2019-10-25 | Iniziato | H.C. Wainwright | Buy |
2019-07-15 | Iniziato | Canaccord Genuity | Buy |
2019-07-15 | Iniziato | Cowen | Outperform |
2019-07-15 | Iniziato | Credit Suisse | Outperform |
2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Is it the right time to buy Stoke Therapeutics Inc. stockExpert guidance for superior capital growth - jammulinksnews.com
How volatile is Stoke Therapeutics Inc. stock compared to the marketSuperior return velocity - jammulinksnews.com
What are analysts’ price targets for Stoke Therapeutics Inc. in the next 12 monthsDiscover market opportunities others miss - jammulinksnews.com
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Explosive trading opportunities - jammulinksnews.com
How does Stoke Therapeutics Inc. generate profit in a changing economyInvest smarter with actionable market insights - jammulinksnews.com
When is Stoke Therapeutics Inc. stock expected to show significant growthGet daily updates on top-performing stocks - jammulinksnews.com
How does Stoke Therapeutics Inc. compare to its industry peersBreakout profit opportunities - jammulinksnews.com
Stoke Therapeutics Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - PrintWeekIndia
Is Stoke Therapeutics Inc. a good long term investmentSuperior return velocity - Autocar Professional
What analysts say about Stoke Therapeutics Inc. stockExtraordinary market timing - Autocar Professional
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Stoke Therapeutics Bets Big On Rare Disease Therapies - Finimize
Stoke Therapeutics Soars 17.02% on Market Optimism - AInvest
What drives Stoke Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser
Published on: 2025-07-22 15:57:09 - jammulinksnews.com
Published on: 2025-07-22 13:02:52 - jammulinksnews.com
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st
Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus
Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada
Published on: 2025-07-18 11:35:29 - jammulinksnews.com
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):